Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 15;28:101727. doi: 10.1016/j.ajoc.2022.101727

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 4 — The graph shows the changes in the laser flare-cell photometer (LFP) flare and logarithm of the minimum angle of resolution visual acuity (logMAR VA) during follow-up. IOI occurred two weeks after intravitreal brolucizumab injection (IVbr) (Week 2) with an increase in the LFP flare (51.2 photon count [pc]/ms) and decline in the logMAR VA (0.40). After the first sub-Tenon's injection of 20 mg triamcinolone acetonide (STTA), the LFP flare decreased and the logMAR VA improved to respective values of 30.3 pc/ms and 0.22 at Day 17, 17.9 pc/ms and 0.15 at Month 1, and 12.2 pc/ms and −0.18 at Month 2. Combination therapy of IVbr and STTA was performed at Months 2 and 5. The LFP flare and logMAR VA were stabilized at 12.0 pc/ms and −0.08 at Month 2.5, 18.1 pc/ms and 0.00 at Month 5, and 16.6 pc/ms and −0.18 at Month 8, respectively. LFP = laser flare-cell photometer; pc/ms = photon count/ms; logMAR VA = logarithm of the minimum angle of resolution visual acuity; IVbr = intravitreal brolucizumab injection; STTA = sub-Tenon's injection of 20 mg triamcinolone acetonide.